Massimo Negrini

Active 1987–2024

130
Papers
51,999
Citations
97
h-index
129
i10-index

Citations

Citations per year for Massimo Negrini1975: 1 citations1986: 1 citations1987: 2 citations1988: 1 citations1989: 4 citations1990: 2 citations1991: 3 citations1992: 9 citations1993: 16 citations1994: 19 citations1995: 44 citations1996: 63 citations1997: 74 citations1998: 81 citations1999: 72 citations2000: 40 citations2001: 65 citations2002: 67 citations2003: 66 citations2004: 92 citations2005: 206 citations2006: 464 citations2007: 796 citations2008: 1,249 citations2009: 1,370 citations2010: 1,412 citations2011: 1,325 citations2012: 1,229 citations2013: 1,070 citations2014: 854 citations2015: 714 citations2016: 525 citations2017: 604 citations2018: 410 citations2019: 1,526 citations2020: 1,399 citations2021: 1,146 citations2022: 730 citations2023: 500 citations2024: 616 citations2025: 250 citations2026: 5 citations1976–1985: no citations, so these years are not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 4,520 citing papers, 25.8% of this breakdownChina: 3,446 citing papers, 19.7% of this breakdownItaly: 1,104 citing papers, 6.3% of this breakdownGermany: 702 citing papers, 4% of this breakdownUnited Kingdom: 667 citing papers, 3.8% of this breakdownJapan: 534 citing papers, 3% of this breakdownIndia: 428 citing papers, 2.4% of this breakdownCanada: 403 citing papers, 2.3% of this breakdownIran: 375 citing papers, 2.1% of this breakdownSpain: 372 citing papers, 2.1% of this breakdownFrance: 371 citing papers, 2.1% of this breakdownAustralia: 360 citing papers, 2.1% of this breakdown
0%25.8%Other 24.3%

Fields

  • Biochemistry, Genetics and Molecular Biology78.5%
  • Medicine17.4%
  • Immunology and Microbiology1.6%
  • Neuroscience0.8%
  • Agricultural and Biological Sciences0.5%
  • Engineering0.3%
  • Other0.9%

Topics

  • MicroRNA in disease regulation19.8%
  • Cancer-related molecular mechanisms research12.1%
  • Circular RNAs in diseases11.1%
  • RNA modifications and cancer5%
  • RNA Interference and Gene Delivery2.7%
  • RNA Research and Splicing2.6%
  • Other46.7%

Coauthors

All papers

Open in search
  1. Frequent deletions and down-regulation of micro- RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia

    Authors: , , , , , , , , , , , , , , - National Academy of Sciences, Proceedings of the National Academy of Sciences 2002 cited by 5,018

  2. A microRNA expression signature of human solid tumors defines cancer gene targets

    Authors: , , , , , , , , , , , , , , , , , - National Academy of Sciences, Proceedings of the National Academy of Sciences 2006 cited by 5,696

  3. miR-15 and miR-16 induce apoptosis by targeting BCL2

    Authors: , , , , , , , , , , , , , , , , - National Academy of Sciences, Proceedings of the National Academy of Sciences 2005 cited by 3,521

  4. Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers

    Authors: , , , , , , , , , , - National Academy of Sciences, Proceedings of the National Academy of Sciences 2004 cited by 4,111

  5. MicroRNA Gene Expression Deregulation in Human Breast Cancer

    Authors: , , , , , , , , , , , , , , , , , , , - Cancer Research 2005 cited by 4,059

  6. Small extracellular vesicles deliver miR‐21 and miR‐217 as pro‐senescence effectors to endothelial cells

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Cristian Bassi, Massimo Negrini, Paolo Garagnani, Claudio Franceschi, Jacopo Sabbatinelli, Massimiliano Bonafè, Fabiola Olivieri - Journal of Extracellular Vesicles 2020 cited by 187

  7. P2X7 promotes metastatic spreading and triggers release of miRNA-containing exosomes and microvesicles from melanoma cells

    Authors: , , , , , , , , , , , - Cell Death and Disease 2021 cited by 99

  8. A MicroRNA Signature of Hypoxia

    Authors: , , , , , , , , , , , - Molecular and Cellular Biology 2006 cited by 1,062

  9. MiR-494 induces metabolic changes through G6pc targeting and modulates sorafenib response in hepatocellular carcinoma

    Authors: , , , , , , , , , , , , , , , , , , , - Journal of Experimental & Clinical Cancer Research 2023 cited by 37

  10. MiR-15a and miR-16-1 cluster functions in human leukemia

    Authors: , , , , , , , , , , , , , , , , , - National Academy of Sciences, Proceedings of the National Academy of Sciences 2008 cited by 806

  11. CCAT2, a novel noncoding RNA mapping to 8q24, underlies metastatic progression and chromosomal instability in colon cancer

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Itsuki Taniguchi, Min‐Ae Song, Steven Gallinger, Graham Casey, Stephen N. Thibodeau, Loı̈c Le Marchand, Maarit Tiirikainen, Sendurai A. Mani, Wei Zhang, Ramana V. Davuluri, Koshi Mimori, Masaki Mori, Anieta M. Sieuwerts, John W.M. Martens, Ian Tomlinson, Massimo Negrini, Ioana Berindan‐Neagoe, John A. Foekens, Stanley R. Hamilton, Giovanni Lanza, Scott Kopetz, Riccardo Fodde, George A. Călin - Genome Research 2013 cited by 611

  12. A MicroRNA Signature Associated with Prognosis and Progression in Chronic Lymphocytic Leukemia

    Authors: , , , , , , , , , , , , , , , , , , , , , , - New England Journal of Medicine 2005 cited by 2,412

  13. Combining Anti-Mir-155 with Chemotherapy for the Treatment of Lung Cancers

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Ramana V. Davuluri, Ioana Berindan‐Neagoe, Massimo Negrini, Ignacio I. Wistuba, Hagop M. Kantarjian, Anil K. Sood, Gabriel Lopez‐Berestein, Michael J. Keating, Muller Fabbri, George A. Călin - Clinical Cancer Research 2016 cited by 184

  14. Cyclin G1 Is a Target of miR-122a, a MicroRNA Frequently Down-regulated in Human Hepatocellular Carcinoma

    Authors: , , , , , , , , , , , , - Cancer Research 2007 cited by 812

  15. MiR-221 controls CDKN1C/p57 and CDKN1B/p27 expression in human hepatocellular carcinoma

    Authors: , , , , , , , , , , - Oncogene 2008 cited by 641

  16. In Hepatocellular Carcinoma miR-221 Modulates Sorafenib Resistance through Inhibition of Caspase-3–Mediated Apoptosis

    Authors: , , , , , , , , , , , , , , , , , , - Clinical Cancer Research 2017 cited by 172

  17. Characterization of the Mammalian YAP (Yes-associated Protein) Gene and Its Role in Defining a Novel Protein Module, the WW Domain

    Authors: , , , , , , , - Journal of Biological Chemistry 1995 cited by 338

  18. Circulating miR-106b-3p, miR-101-3p and miR-1246 as diagnostic biomarkers of hepatocellular carcinoma

    Authors: , , , , , , , , , , , , , , , , , , , , , - Oncotarget 2018 cited by 97

  19. Extensive modulation of a set of microRNAs in primary glioblastoma

    Authors: , , , , , , , , , - Biochemical and Biophysical Research Communications 2005 cited by 1,098

  20. Downregulation of the Mitochondrial Calcium Uniporter by Cancer-Related miR-25

    Authors: , , , , , , , , , , , , , , , - Current Biology 2012 cited by 232

  21. The epigenetically regulated miR-494 associates with stem-cell phenotype and induces sorafenib resistance in hepatocellular carcinoma

    Authors: , , , , , , , , , , , , , , , - Cell Death and Disease 2018 cited by 104

  22. microRNA-29 can regulate expression of the long non-coding RNA gene MEG3 in hepatocellular cancer

    Authors: , , , , , , , , , - Oncogene 2011 cited by 666

  23. MiR-199a-3p Regulates mTOR and c-Met to Influence the Doxorubicin Sensitivity of Human Hepatocarcinoma Cells

    Authors: , , , , , , , , , - Cancer Research 2010 cited by 397

  24. Modulation of mismatch repair and genomic stability by miR-155

    Authors: , , , , , , , , , , , , , , , , , , , , , , , - National Academy of Sciences, Proceedings of the National Academy of Sciences 2010 cited by 350